Skip to main content

Pixium Vision to present the 12-month data of its Dry-AMD Prisma system at the 11th Eye and The Chip World Research Congress on Artificial Vision

Paris, France. November 08, 2019 – 05.45 PM CET– Pixium Vision (FR0011950641 – PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, announce its participation to the 11th Eye and The Chip World Research Congress1 – Dearborn, MI, USA.This congress will provide an opportunity to Pr. Daniel Palanker, Stanford University and to Dr Yannick Le Mer, Fondation Adophe de Rothschild, Medical and Scientific advisor to Pixium-Vision to present the positive results at 12 months of the Prisma system in patients affected by dry age-related macular degeneration. This presentation will take place on November 10, 2019 during the session Current Clinical Trials, Patient Outcomes and Experiences.The Detroit Institute of Ophthalmology is the research education arm of the Henry Ford Department of Ophthalmology, and sponsors two international research congresses, including the Eye and The Chip World Research Congress. These two international events gather the most renowned scientists over three days. The primary goal of the Eye and The Chip World Research Congress is to marry the most recent advances in nanoelectronics and neurobiology to provide artificial vision to many people who are now blind as a result of many eye conditions, diseases and injuries.Communication
Sunday 10th November 2019
From 9:00am to 9:30am EST
Session 1 – Current Clinical Trials, Patient Outcomes and ExperiencesModerator – Lauren Ayton, Ph.D., University of Melbourne, Melbourne, AustraliaTitlePhotovoltaic Restoration of Sight in Age-related Macular Degeneration: One-Year Clinical ResultsSpeakers  Daniel Palanker, Ph.D., Stanford University, Stanford, CaliforniaYannick Le Mer, M.D., Fondation Ophtalmologique A. de Rothschild, Paris, France1 – Detroit Institute of Ophthalmology and the Henry Ford Department of OphthalmologyContacts Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.For more information :  http://www.pixium-vision.com/fr
Follow us on @PixiumVision;  www.facebook.com/pixiumvision
              www.linkedin.com/company/pixium-vision Speakers  Daniel Palanker, Ph.D., Stanford University, Stanford, CaliforniaYannick Le Mer, M.D., Pixium-Vision, Paris, France1 Attachment2019-11-06 – PR Eye and the Chip Congress – EN_RH

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.